期刊論文1. | Wu, Chuan-feng(20100300)。Raising the Right to Health Concerns Within the Framework of International Intellectual Property Law。Asian Journal of WTO & International Health Law and Policy,5(1),141-205。 |
2. | 李素華(20120600)。醫藥發明之專利個案探討:以我國長青樹藥品專利為例。國立臺灣大學法學論叢,41(2),647-723。 延伸查詢 |
3. | Reichman, Jerome H.(2009)。Rethinking the Role of Clinical Trial Data in International Intellectual Property Law: The Case for a Public Goods Approach。Marquette Intellectual Property Law Review,13(1),1-68。 |
4. | Hogges-Thomas, Alica I.(2013)。An American Drug Problem: Reclaiming Consumers' Rights under the Hatch-Waxman Act。VT. L. REV.,37,737-762。 |
5. | 李素華(20161200)。我國藥品專利保護之現況與未來--從專利連結制度之研擬談起。智慧財產權月刊,216,5-28。 延伸查詢 |
6. | 李素華、吳全峰(20161100)。初探藥事法增訂專利連結專章之立法芻議。月旦法學,258,163-177。 延伸查詢 |
7. | 葉雲卿(20130600)。藥品試驗資料專屬權近期國際發展之趨勢--我國資料專屬權制度及因應國際趨勢應有之調整。智慧財產評論,11(1),31-86。 延伸查詢 |
8. | Flynn, Sean M.、Baker, Brook K.、Kaminski, Margot E.、Koo, Jimmy(20121204)。The U.S. Proposal for an Intellectual Property Chapter in the Trans-Pacific Partnership Agreement。American University International Law Review,28(1),105-202。 |
9. | 吳全峰(20161200)。我國藥品資料專屬保護制度之修法趨勢與展望--從新適應症新藥之資料專屬保護談起。智慧財產權月刊,216,29-54。 延伸查詢 |
10. | 張哲倫(20150400)。專利連結之歷史、緣由及其政策功能。智慧財產權月刊,196,5-19。 延伸查詢 |
11. | 陳翠華(20080600)。我國醫藥品專利權期間延長制度之探討。智慧財產權月刊,114,63-99。 延伸查詢 |
12. | Adelman, David E.、Holman, Christopher M.(2010)。Misplaced Fears in the Battle over Affordable Biotech Drugs。IDEA,50,565-591。 |
13. | Bhardwaj, Ravikant(2013)。The Impact of Patent Linkage on Marketing of Generic Drugs。J. Intell. Prop. Rts.,18,316-322。 |
14. | Courage, Noel、Parsons, Ainslie(2011)。The Comparability Conundrum: Biosimilars in the United States, Europe and Canada。Food & Drug L. J.,66(2),203-224。 |
15. | Hemphill, C. Scott、Lemley, Mark A.(2011)。Earning Exclusivity: Generic Drug Incentives and the Hatch-Waxman Act。Antitrust Law Journal,77,947-952。 |
16. | Kilic, Burcu(2015)。What Is Patentable Under the Trans-Pacific Partnership?: An Analysis of the Free Trade Agreement's Patentability Provisions from a Public Health Perspective。Yale Journal of International Law Online,40(1)。 |
17. | Lybecker, Kristina M.(2014)。When Patents Aren't Enough: Why Biologics Necessitate Date Exclusivity Protection。William Mitchell Law Review,40,1427-1431。 |
18. | Seamon, Matthew J.(2010)。Antitrust and the Biopharmaceutical Industry: Lessons from Hatch-Waxman and an Early Evaluation of the Biologics Price Competition and Innovation Act of 2009。Nova Law Review,34,629-657。 |
19. | Tzeng, Linfong(2010)。Follow-On Biologics, Data Exclusivity, and the FDA。Berkeley Tech. L. J.,25,135-158。 |
20. | 王立達、陳蔚奇(20101200)。學名藥上市審查之專利連結制度:從美國經驗檢證其存立基礎與制度設計。國立臺灣大學法學論叢,39(4),349-406。 延伸查詢 |